Cargando…
New Insights into the Binding Features of F508del CFTR Potentiators: A Molecular Docking, Pharmacophore Mapping and QSAR Analysis Approach
Cystic fibrosis (CF) is the autosomal recessive disorder most recurrent in Caucasian populations. To combat this disease, many life-prolonging therapies are required and deeply investigated, including the development of the so-called cystic fibrosis transmembrane conductance regulator (CFTR) modulat...
Autores principales: | Righetti, Giada, Casale, Monica, Tonelli, Michele, Liessi, Nara, Fossa, Paola, Pedemonte, Nicoletta, Millo, Enrico, Cichero, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762081/ https://www.ncbi.nlm.nih.gov/pubmed/33291847 http://dx.doi.org/10.3390/ph13120445 |
Ejemplares similares
-
Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors
por: Righetti, Giada, et al.
Publicado: (2020) -
Probing Allosteric Hsp70 Inhibitors by Molecular Modelling Studies to Expedite the Development of Novel Combined F508del CFTR Modulators
por: Sabbadini, Roberto, et al.
Publicado: (2021) -
Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays
por: Parodi, Alice, et al.
Publicado: (2022) -
Recent Strategic Advances in CFTR Drug Discovery: An Overview
por: Rusnati, Marco, et al.
Publicado: (2020) -
NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis
por: Brandas, Chiara, et al.
Publicado: (2021)